Victor Sunita Prem, Gayathri Devi M G, Paul Willi, Vijayan Vineeth M, Muthu Jayabalan, Sharma Chandra P
Division of Polymeric Medical Devices, ‡Biosurface Technology, §Polymer Division, ∥Central Analytical Facility Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Poojappura, Thiruvananthapuram 695012, India.
Division of Polymeric Medical Devices, Biosurface Technology, §Polymer Division, ∥Central Analytical Facility Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Poojappura, Thiruvananthapuram 695012, India.
ACS Biomater Sci Eng. 2017 Dec 11;3(12):3588-3595. doi: 10.1021/acsbiomaterials.7b00453. Epub 2017 Nov 7.
We present the development of theranostic nanoplatforms (NPs) based on a europium (Eu) doped calcium deficient hydroxyapatite (CDHA) core functionalized with cyclodextrin (β-CD) and cucurbitural (CB[7]). The composition, crystalline structure, aspect ratio, surface area, morphology, and luminescence property of the NPs were investigated by means of X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), energy dispersive X-ray analysis (EDAX), the Brunauer-Emmett-Teller (BET) method, transmission electron microscopy (TEM), and fluorescence spectroscopy. The perceivable effects of Eu doping appear in the minor peak shift to larger angles attributed to lower crystallite size and smaller aspect ratios coupled with greater structural strain in the rod shaped theranostic NPs and a shift in their zeta potential toward less negative values. Cell parameter calculations suggest that the doping of Eu would cause the -axis parameter to decrease slightly as the ionic radius of Eu is smaller than that of Ca. Moreover drug release profiles employing 5-fluorouracil (5FU) suggest that these luminescent NPs depict controlled and sustained release profiles. Further the emissive intensities of the NPs in the carrier systems increase with cumulative released amounts of 5FU, suggesting that release of the drug can be monitored by changes in luminescent intensity. In addition, native NPs manifest commendable cytocompatibility as demonstrated by MTT and live/dead protocols, whereas the 5FU loaded NPs demonstrated over 80% HeLa cell death, signifying their therapeutic potential. We envision that these NPs can serve as effective and practical multifunctional probes for theranostic applications.
我们展示了基于用环糊精（β-CD）和葫芦脲（CB[7]）功能化的铕（Eu）掺杂缺钙羟基磷灰石（CDHA）核的诊疗纳米平台（NPs）的开发。通过X射线衍射（XRD）、傅里叶变换红外光谱（FTIR）、能量色散X射线分析（EDAX）、布鲁诺尔-埃米特-泰勒（BET）法、透射电子显微镜（TEM）和荧光光谱对NPs的组成、晶体结构、纵横比、表面积、形态和发光特性进行了研究。Eu掺杂的可感知效应表现为在较小角度处的小峰位移，这归因于棒状诊疗NPs中较低的微晶尺寸和较小的纵横比以及更大的结构应变，以及它们的zeta电位向较不负值的偏移。晶胞参数计算表明，由于Eu的离子半径小于Ca，Eu的掺杂会导致a轴参数略有下降。此外，采用5-氟尿嘧啶（5FU）的药物释放曲线表明，这些发光NPs呈现出可控和持续的释放曲线。此外，载体系统中NPs的发射强度随着5FU的累积释放量增加，表明药物的释放可以通过发光强度的变化来监测。此外，如MTT和活/死实验方案所示，天然NPs表现出良好的细胞相容性，而负载5FU的NPs显示超过80%的HeLa细胞死亡，表明它们的治疗潜力。我们设想这些NPs可以作为用于诊疗应用的有效且实用的多功能探针。
